Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic Dermatitis
Conditions
Interventions
ARQ-154
Locations
39
United States
Arcutis Biotherapeutics Clinical Site 59
Beverly Hills, California, United States
Arcutis Biotherapeutics Clinical Site 51
Encino, California, United States
Arcutis Biotherapeutics Clinical Site 75
Fountain Valley, California, United States
Arcutis Biotherapeutics Clinical Site 19
Fremont, California, United States
Arcutis Biotherapeutics Clinical Site 62
Los Angeles, California, United States
Arcutis Biotherapeutics Clinical Site 64
San Diego, California, United States
Start Date
June 12, 2020
Primary Completion Date
November 19, 2022
Completion Date
November 19, 2022
Last Updated
June 11, 2024
NCT05319444
NCT01703793
NCT00565279
Lead Sponsor
Arcutis Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions